Inotiv Inc (NOTV)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
$0.01-26.00%
Close 2026-07-17 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
Research Workspace
Put NOTV beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Primary pillar under pressure — Address Nasdaq delisting notice and regain listing compliance: Delisting risk realized via Chapter 11 filing.
View ThesisRevenue is growing steadily — about 6% over the past year.
View GrowthManagement screens weak on capital allocation, earnings delivery, the balance sheet, market reaction to earnings.
View ManagementThis stock is volatile — it swings about 6% on a typical day and fell roughly 99% in its worst 12-month stretch.
View RiskNOTV’s thesis rests on recovery from Chapter 11 and regained Nasdaq listing compliance. Yet its unprofitable year and weak performance leave that recovery unsupported. The latest recorded earnings surprise was a 49% miss. The model puts next-quarter miss probability at 75%. No valuation multiple or priced-in read is available in the desk. Chapter 11 filing realized the delisting-risk pillar. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-07-17. NOTV is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering NOTV (as of Jun 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare NOTV with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NOTV Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put NOTV next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Restructuring through Chapter 11 proceedings
Bankruptcy filing directly impacts restructuring efforts.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-17. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Manage financial obligations under Chapter 11
Debt reduction plan supports financial obligations management.
Threatens: Manage financial obligations under Chapter 11
Earnings miss indicates financial strain affecting obligations.